Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light ScatterBusiness Wire • 04/02/25
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy SpaceZacks Investment Research • 03/31/25
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial DiseaseBusiness Wire • 03/26/25
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark ApprovalZacks Investment Research • 03/25/25
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual PossibilitiesBusiness Wire • 03/25/25
Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl ZeissGlobeNewsWire • 03/24/25
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded ParametersBusiness Wire • 02/27/25
Alcon Q4 Earnings Beat, Margins Rise, Stock Remains Stable in AfterhoursZacks Investment Research • 02/26/25
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash GenerationBusiness Wire • 02/25/25
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula YetBusiness Wire • 02/24/25
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 EarningsZacks Investment Research • 02/20/25
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular HypertensionBusiness Wire • 02/19/25